CCM Investment Group LLC Invests $5.77 Million in Pfizer Inc. (NYSE:PFE)

CCM Investment Group LLC purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 228,990 shares of the biopharmaceutical company's stock, valued at approximately $5,773,000. Pfizer makes up about 0.6% of CCM Investment Group LLC's holdings, making the stock its 25th biggest position.

• Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Nuveen LLC purchased a new stake in shares of Pfizer in the first quarter worth about $389,861,000. Cooper Financial Group lifted its holdings in shares of Pfizer by 10.3% in the first quarter. Cooper Financial Group now owns 18,314 shares of the biopharmaceutical company's stock worth $464,000 after buying an additional 1,716 shares in the last quarter. King Luther Capital Management Corp lifted its holdings in shares of Pfizer by 6.5% in the first quarter. King Luther Capital Management Corp now owns 2,698,932 shares of the biopharmaceutical company's stock worth $68,391,000 after buying an additional 163,847 shares in the last quarter. American Alpha Advisors LLC purchased a new stake in shares of Pfizer in the first quarter worth about $418,000. Finally, Virtu Financial LLC lifted its holdings in shares of Pfizer by 41.5% in the first quarter. Virtu Financial LLC now owns 242,292 shares of the biopharmaceutical company's stock worth $6,140,000 after buying an additional 71,102 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. The Goldman Sachs Group raised their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Finally, Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $28.12.

• Top 5 Undervalued Dividend Stocks With Strong Payout Potential

Get Our Latest Report on PFE

Pfizer Stock Up 1.4%

Shares of Pfizer stock opened at $24.57 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.96 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The stock has a market capitalization of $139.69 billion, a price-to-earnings ratio of 13.07, a P/E/G ratio of 0.89 and a beta of 0.52. The company's 50 day moving average price is $24.44 and its 200-day moving average price is $24.49.

• Pfizer's 7.5% Dividend: Income Haven or House of Cards?

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $0.60 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

• Five stocks we like better than Pfizer
• What Makes a Stock a Good Dividend Stock?
• Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?
• Compound Interest and Why It Matters When Investing
• Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
• What does consumer price index measure?
• Now Is a Great Time to Buy Cheniere Energy: New High Expected

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here